A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma

Inclusion Criteria:

Confirmation of cancer by biopsy (tissue sample)
Phase 1: patients with advanced or metastatic disease that have failed conventional therapy
Phase 2: patients with previously untreated NSCLC, excluding squamous cell histology and cavitating lesions
Age ≥18 years
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Adequate renal, liver and bone marrow function.
Negative pregnancy test (serum or urine) in females of childbearing potential within 7 days of the initial dose of aflibercept
Ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
Institutional Review Board (IRB) approved, signed and dated informed consent form

Exclusion Criteria:

Prior treatment with study medications
Untreated, symptomatic, or progressive Central Nervous System cancer and/or spinal cord compression. Patients with treated brain metastases must have been without symptoms for at least 3 months
Surgery up to 4 weeks prior to the initial administration of aflibercept and/or incomplete wound healing
Anti-VEGF therapy up to 4 weeks prior to the initial administration of aflibercept (for phase 1 only)
Chemotherapy up to 4 weeks prior to the initial administration of aflibercept (for phase 1 only)
Other investigational treatment up to 4 weeks prior to the initial administration of aflibercept

Any of the following up to 6 months (24 weeks) prior to the initial administration of aflibercept:

Severe cardiovascular disease or event
Cerebrovascular accident, transient ischemic attack, or moderate to severe peripheral neuropathy
Erosive esophagitis or gastritis, infectious or inflammatory bowel disease, and diverticulitis
Deep vein thrombosis, pulmonary embolism, or other clotting event
Episode(s)of moderate to severe, continuous bleeding
Breast-feeding or pregnancy